VPA-985, a Nonpeptide Orally Active and Selective Vasopressin V2 Receptor Antagonist
The introduction of the thiazides as orally-active diuretics about forty years ago (1), and other more effective low-ceiling diuretics thereafter, revolutionized the treatment of edema, ascites, hypertension and related diseases. Later, the addition of potent high-ceiling (loop) and potassium-sparing diuretics provided clinicians with a wide choice of diuretics to eliminate retained sodium and water (2). However, it was soon evident that many patients became refractory to these saluretic agents and some developed hyponatremia (serum sodium < 130 mEq/L) (3, 4, 5). Hyponatremia also occurs in the syndrome of inappropriate antidiuretic hormone secretion (SIADH), in patients with congestive heart failure (CHF), liver cirrhosis with ascites, renal failure, and many other disorders where the plasma vasopressin concentrations are inappropriately high for any given plasma osmolality. Under these conditions, an aquaretic (water diuretic), not a conventional diuretic, would be the drug of choice to promote the excretion of the retained body water and to normalize plasma osmolality and sodium concentration (6, 7, 8). As vasopressin (AVP, antidiuretic hormone (ADH)) acting at V2 receptors in the collecting ducts controls water re-absorption (7, 8), considerable effort has been spent over many years to develop vasopressin Vz receptor antagonists or agents that could inhibit the release of vasopressin from the posterior pituitary (8,9). Many peptide vasopressin analogs have been developed as vasopressin V2 receptor antagonists, and two of them, SK&F 101926 and SK&F 105494, showed excellent V2 antagonistic activity in many animal models, including nonhuman primates. Unfortunately, in humans, both compounds behaved as vasopressin V2 agonists (9). Recently, three nonpeptidic and orally active vasopressin receptor antagonists have been described in the literature. The first two, OPC-31260 (10), and SR 121463A (11), are V2 selective, while the third compound, YM087 (12), is a dual V1a/V2 receptor antagonist.
KeywordsCarbonyl Vasopressin Tricyclic Furosemide Oxytocin
Unable to display preview. Download preview PDF.
- 2.Cervoni P, and Chan PS 1993 Diuretic Agents, In Kirk-Othmer: Encyclopedia of Chemical Technology, 4th Ed., Wiley, Volume 8, pp. 398–432Google Scholar
- 5.Wilcox CS 1996 Diuretics. In Brenner & Rector’s The Kidney. 5th Ed Brenner BM Ed WB Saunders Philadelphia pp 2299–2330Google Scholar
- 8.László FA, László F Jr 1993 Clinical perspectives for vasopressin antagonists. Drug News & Perspective, 6:591–599Google Scholar
- 9.Ruffolo RR Jr, Brooks DP, Huffman WF, Poste G 1991 From vasopressin antagonist to agonist: A saga of surprise. Drug News & Perspectives, 4:217–222Google Scholar
- 10.Yamamura Y, Ogawa H, Yamashita H, Chihara T, Miyamoto H, Nakamura S, Onogawa T, Yamashita T, Hosokawa T, Mori T, Tominaga, Yabuuchi Y 1992 Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist. Brit J Pharmacol 105:787–791CrossRefGoogle Scholar
- 11.Serradeil-Le Gal C, Lacour C, Valette G, Garcia G, Foulon L.., Galindo G, Bankir L, Pouzet B, Guillon G, Barberis C, Chicot D, Jard S, Vilain P, Garcia C, Marty E, Raufaste D, Brossard G, Nisato D, Maffrand JP, Le Fur G 1996 Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist. J Clin Invest 98:2729–2738PubMedCrossRefGoogle Scholar
- 13.Albright JD, Reich MF, Sum FW, Delos Santos EG 1996 Tricyclic diazepine vasopressin antagonists and oxytocin antagonists. U. S. Patent No. 5,516,774 (May 14, 1996).Google Scholar
- 14.Abraham WT, Oren RM, Crisman TS, Robertson AD, Shaker S, Lowes BD, Panther L, Kelley P, Pies CJ, Bristow MR, Schrier RW 1997 Effects of an oral, nonpeptide, selective V2 receptor vasopressin antagonist in patients with chronic heart failure. Am Coll Cardiol 29 (2 Suppl. A):169A.Google Scholar